1391423-36-1

Basic information

• Product Name: tert-butyl 4-amino-1-phenylbutan-2-ylcarbamate
• CAS NO: 1391423-36-1
• Molecular Weight: 264.368
• Mol File: 1391423-36-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-amino-1-phenylbutan-2-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-amino-1-phenylbutan-2-ylcarbamate(1391423-36-1)
• EPA Substance Registry System: tert-butyl 4-amino-1-phenylbutan-2-ylcarbamate(1391423-36-1)

Safety Data

• Hazardous Substances Data: 1391423-36-1(Hazardous Substances Data)

Upstream product

• 3182-95-4 L-Phenylalaninol 
• 120378-17-8 threo-(2RS)-3-t-butoxycarbonylamino-4-phenylbutanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 126301-19-7 (2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropyl methanesulfonate 
• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 
• 172695-25-9 (S)-3-<(tert-butoxycarbonyl)amino>-4-phenylbutanenitrile 

Relevant articles and documents

Development of Chiral Organosuperbase Catalysts Consisting of Two Different Organobase Functionalities

In the field of chiral Br?nsted base catalysis, a new generation of chiral catalysts has been highly anticipated to overcome the intrinsic limitation of pronucleophiles that are applicable to the enantioselective reactions. Herein, we reveal conceptually new chiral Br?nsted base catalysts consisting of two different organobase functionalities, one of which functions as an organosuperbase and the other as the substrate recognition site. Their prominent activity, which stems from the distinctive cooperative function by the two organobases in a single catalyst molecule, was demonstrated in the unprecedented enantioselective direct Mannich-type reaction of α-phenylthioacetate as a less acidic pronucleophile. The present achievement would provide a new guiding principle for the design and development of chiral Br?nsted base catalysts and significantly broaden the utility of Br?nsted base catalysis in asymmetric organic synthesis.

METHODS FOR INHIBITING DRUG DEGRADATION

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters

HIV PROTEASE INHIBITOR AND CYTOCHROME P450 INHIBITOR COMBINATIONS

Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of disea